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BACKGROUND: The PI3K–mTOR (phosphoinositide 3-kinase–mammalian target of rapamycin kinase) pathway is activated in the
majority of tumours, and there is interest in assessing whether inhibitors of PI3K or mTOR kinase have efficacy in treating cancer.
Here, we define the effectiveness of specific mTOR (AZD8055) and PI3K (GDC-0941) inhibitors, currently in clinical trials, in treating
spontaneous B-cell follicular lymphoma that develops in PTEN
þ/ LKB1
þ/hypo mice.
METHODS: The PTEN
þ/ LKB1
þ/hypo mice were administered AZD8055 or GDC-0941, and the volumes of B-cell follicular lymphoma
were measured by MRI. Tumour samples were analysed by immunohistochemistry, immunoblot and flow cytometry.
RESULTS: The AZD8055 or GDC-0941 induced B40% reduction in tumour volume within 2 weeks, accompanied by ablation of
phosphorylation of AKT, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. The drugs reduced tumour cell
proliferation, promoted apoptosis and suppressed centroblast population. The AZD8055 or GDC-0941 treatment beyond 3 weeks
caused a moderate additional decrease in tumour volume, reaching B50% of the initial volume after 6 weeks of treatment. Tumours
grew back at an increased rate and displayed similar high grade and diffuse morphology as the control untreated tumours upon
cessation of drug treatment.
CONCLUSION: These results define the effects that newly designed and specific mTOR and PI3K inhibitors have on a spontaneous
tumour model, which may be more representative than xenograft models frequently employed to assess effectiveness of kinase
inhibitors. Our data suggest that mTOR and PI3K inhibitors would benefit treatment of cancers in which the PI3K pathway is
inappropriately activated; however, when administered alone, may not cause complete regression of such tumours.
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The majority of human cancers possess mutations in signal
transduction components that lead to the over-activation of
phosphoinositide 3-kinase (PI3K) and mammalian target of
rapamycin kinase (mTOR) signalling pathways. The PI3K is
activated downstream of growth factor receptors and phospho-
rylates phosphatidyl 4,5-bisphosphate (PtdIns(4,5)P2) to produce
the PtdIns(3,4,5)P3 second messenger. This promotes the activa-
tion of the 3-phosphoinositide-dependent protein kinase-1 (PDK1)
as well as the two mTOR multiprotein complexes, mTOR complex-1
(mTORC1; including mTOR, Raptor and mLST8) and mTOR
complex-2 (mTORC2; including mTOR, Rictor, Sin1, mLST8 and
Protor), which will lead in turn to the activation of downstream
kinases including isoforms of Akt, p70 ribosomal S6 kinase (S6K)
and the serum and glucocorticoid protein kinase (SGK) (Pearce
et al, 2010). Activation of this signalling network has vital roles in
promoting growth, survival and proliferation of cancer cells
(Engelman et al, 2006). The importance of this network in cancer
is emphasised by the finding that many cancer-driving mutations
stimulate this pathway. These include activating mutations of the
catalytic subunit of PI3K-a (Samuels et al, 2004) or mutations that
inactivate the lipid phosphatase and tensin homologue deleted on
chromosome 10 (PTEN) that degrades PtdIns(3,4,5)P3 (Sulis and
Parsons, 2003; Leslie and Downes, 2004). Consistent with this,
heterozygous PTEN
þ/  mice spontaneously develop a variety of
tumours after 8 months of age (Di Cristofano et al, 1998; Haas-
Kogan et al, 1998; Maehama and Dixon, 1998; Myers et al, 1998;
Stambolic et al, 1998; Suzuki et al, 1998; Podsypanina et al, 1999),
and importantly, tumour development in PTEN-deficient mice is
significantly suppressed by genetic disruption of PDK1 (Bayascas
et al, 2005; Wullschleger et al, 2010), mTOR complex components
(Guertin et al, 2009) or Akt (Chen et al, 2006).
These observations have led to huge efforts to develop inhibitors
that suppress the PI3K and mTOR pathways that are beginning to
be evaluated in clinical trials (Engelman, 2009). Two such
compounds are GDC-0941, a PI3K inhibitor (Folkes et al, 2008;
Salphati et al, 2010), and AZD8055, an mTOR inhibitor (Chresta
et al, 2010). The GDC-0941 inhibits all class 1 PI3K isoforms (IC50
of 3nM PI3K-a,3 3n M PI3K-b,3n M PI3K-d and 75nM PI3K-g) but
does not significantly suppress the activity of any other lipid or
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sprotein kinase tested including mTOR (Folkes et al, 2008). The
AZD8055 is also a remarkably potent mTOR kinase inhibitor (IC50
of 0.13nM), suppressing activity of both mTORC1 and mTORC2
without inhibiting PI3K isoforms or any other lipid or protein
kinases tested (Chresta et al, 2010). Recent pharmacokinetic–
pharmacodynamic data indicate that GDC-0941 (Salphati et al,
2010) and AZD8055 (Chresta et al, 2010) are well tolerated and
effective in mice, and these studies have also shown that GDC-0941
and AZD8055 slow the growth of several cancer cells that have
elevated PI3K pathway activity in xenografts mice models.
In this study, we evaluated the effects that administration of
GDC-0941 or AZD8055 had on spontaneous B-cell follicular
lymphomas developed in 6- to 8-month-old heterozygous
PTEN
þ/ LKB1
þ/hypo mice. Our data suggests that, at least for
this type of tumour driven by activation of the PI3K and mTOR
pathway, single-agent administration of drugs that suppress these
pathways would be effective at shrinking tumours and inhibiting
their growth, but would not cause complete regression.
MATERIALS AND METHODS
Materials
Protein G-Sepharose was purchased from Amersham Bioscience
(Uppsala, Sweden);
32Pg-ATP was from Perkin-Elmer (Boston, MA,
USA); Tween-20 and DMSO were from Sigma (Steinheim, Germany);
and CHAPS was from Calbiochem (La Jolla, CA, USA). The GDC-
0941 was synthesised by Dr Natalia Shpiro at the University of
Dundee. The AZD8055 was provided by AstraZeneca (Alderley Park,
Cheshire, UK). For studies in mice, both drugs were dissolved in a
final captisol (CyDex, Lenexa, KS, USA) concentration of 30%
(w/v). The GDC-0941 (75mgkg
 1)a n dA Z D 8 0 5 5( 2 0m gk g
 1)w e r e
administered by oral gavage once daily for up to 42 days.
Mice breeding, genotyping and tumour analysis
All animal studies were approved by the University of Dundee Ethics
Committee and performed under a UK Home Office project license.
The generation and genotyping of the PTEN
þ/  mice (Podsypanina
et al, 1999) the LKB1 hypomorphic mice (Sakamoto et al, 2005) have
been described previously. The parental LKB1
þ/hypo and PTEN
þ/ 
used for these experiments had been backcrossed with C57BL/6J for
over seven generations before initiating the crosses for the present
study. Littermates with different genotypes of LKB1 and PTEN were
generated and maintained under standard husbandry conditions for
a period of up to 14 months of age. During this period, mouse weight
and blood glucose levels were routinely monitored. Onset of tumour
formation was monitored by weekly palpation of the major lymph
nodes. According to our UK Home Office license, any animal that
displayed an obvious external tumour of over 1.44cm
2 or showed
signs of sickness was culled. The tissues were fixed in 10% formalin
and subjected to necropsy and pathological analysis. Tumour slices
were generated and analysed as described previously (Bayascas et al,
2005).
Magnetic resonance imaging
Mice were anesthetised with 1.5% isoflurane in 100% oxygen using
a nose cone with scavenging. The mice were monitored during
imaging and recovery, and then returned to their cage. The MRI
data were acquired on a Bruker Avance FT NMR spectrometer
(Bruker Biospin GmbH, Rheinstetten, Germany) with a wide-
bore 7.1-Tesla vertical magnet (Oxford Instruments, Abingdon,
Oxfordshire, UK) resonating at 300.15MHz for
1H. A MicroMouse
birdcage radio-frequency resonator (Bruker Biospin GmbH,
Rheinstetten, Germany) with an internal diameter of 30mm was
used. Three-dimensional (3D) 128 by 128 by 128 rapid acquisition
relaxation enhanced (RARE) MRI experiments were performed
with RARE factor of 4, taken from the Paravision library (Bruker
Biospin GmbH). Recycle time (TR) of 250ms and an effective echo
time (TE) of 10ms were used. One acquisition sequence was
acquired to minimise experimental time, which was 16min. The
field of view was 30mm and isotropic image spatial resolution was
234mm per pixel.
MRI data analysis
The MRI data were Fourier transformed and then visualised using
Amira PC-based software (Visage Imaging GmbH, 12163 Berlin,
Germany). This allowed 2D slices to be viewed from any angle within
the 3D data set and allowed digital segmentation. The anatomy of
interest was digitally segmented, 3D finite element meshes generated
and surface rendered to produce 3D surface representations. This
allowed the volumes of the tumours to be calculated.
Buffers
The following buffers were used: Tris lysis buffer (50mM Tris-HCl
(pH 7.5), 1mM EGTA, 1mM EDTA, 0.3 % (w/v) CHAPS, 1mM
sodium orthovanadate, 10mM sodium-b-glycerophosphate, 50mM
sodium fluoride, 5mM sodium pyrophosphate, 0.27 M sucrose,
0.15 M NaCl, 0.1 % (v/v) 2-mercaptoethanol, 1mM benzamidine
and 0.1mM phenylmethylsulphonylfluoride); Buffer A (50mM Tris-
HCl (pH 7.5), 0.1mM EGTA and 0.1% (v/v) 2-mercaptoethanol);
TBS-Tween buffer (50mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.1%
(v/v) Tween-20); and Sample buffer (50mM Tris-HCl (pH 6.8), 6.5%
(v/v) glycerol, 1% (w/v) SDS and 1 % (v/v) 2-mercaptoethanol).
Preparation of tissue lysates
Tissues were extracted, frozen in liquid nitrogen and stored at
 801C. Tissues were homogenised on ice in a 10-fold mass excess
of ice-cold Tris lysis buffer using a Kinematica Polytron
(Kinematica, Littan, Switzerland). Tissue lysates were centrifuged
at 18000g for 15min at 41C, and the supernatant was snap frozen
in aliquots and stored at  801C.
Kinase assays
Tumours were lysed in Tris lysis buffer. To perform Akt and S6K
assays, 500mg of lysate was incubated with 1–5mg of the
corresponding antibody conjugated to protein G-sepharose. All
the incubations were performed for 1h at 41C on a vibrating
platform. Kinase activity was assayed using the crosstide peptide
(GRPRTSSFAEG) at 30mM. Incorporation of [
32P]-phosphate into
the peptide substrate was determined by applying the reaction
mixture on to P81 phosphocellulose paper, and scintillation
counting after washing the papers in phosphoric acid. One unit
of activity was defined as that amount of enzyme that catalysed the
incorporation of 1nmol of [
32P]-phosphate into the substrate.
Immunoblotting
Total tumour lysate (5–20mg) was heated at 951C for 5min in
sample buffer, and subjected to polyacrylamide gel electrophoresis
and electrotransfered to nitrocellulose membrane. Membranes
were blocked for 1h in TBS-Tween buffer containing 10% (w/v)
skimmed milk. The membranes were probed with the indicated
antibodies in TBS-Tween containing 5% (w/v) skimmed milk or
5% (w/v) BSA for 16h at 41C. Detection was performed using
horseradish peroxidase-conjugated secondary antibodies and the
enhanced chemiluminescence reagent.
Antibodies
The following antibodies were raised in sheep and affinity purified
on the appropriate antigen: anti-NDRG1 (S276B, second bleed) was
made in sheep using recombinant GST fusion of full-length
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sNDRG1 (used for immunoblotting). An antibody that recognises
NDRG1 phosphorylated at Thr346, Thr356 and Thr366 (S911B,
second bleed; termed pNDRG1 3xThr-P) was raised against the
nonapeptide RSRSHpTSEG, whose sequence is common to all
three SGK1 phosphorylation sites on NDGR1 (used for immuno-
blotting). Anti-Akt1 (S742B, third bleed) was made in sheep using
recombinant His-Akt1 (used for immunoblotting and immuno-
precipitation), anti-S6K (S417B, second bleed; residues 25–44 of
human S6K AGVFDIDLDQPEDAGSEDEL, used for immunoblot-
ting and immunoprecipitation). Anti-PRAS40 (S115B, first bleed;
residues 238–256 of human PRAS40 DLPRPRLNTSDFQKLKRKY,
used for immunoblotting). An antibody that recognises PRAS40
phosphorylated at Thr246 (S114B, second bleed) was raised against
the residues 240–251 of human PRAS40 CRPRLNTpSDFQK (used
for immunoblotting). Anti-FoxO1 (S504A, 1st bleed) was made in
sheep using recombinant GST-fusion FoxO1 (2-655, used for
immunoblotting). The phospho-Akt Ser473 (no. 9271), Thr308 (no.
4056), phospho-S6K Thr389 no. 9234), phospho-S6 ribosomal
protein Ser235 (no. 4856), total S6 ribosomal protein (no. 2217),
phospho-FoxO1/O3 Thr24/32 (no. 9464), phospho-GSK3a/b Ser21/9
(no. 9331), phospho-4E-BP1 Thr37/Thr46 (no. 9459), phospho-4E-
BP1 Thr65 (no. 9451), phospho-4E-BP1 Ser70 (no. 9455) and
total 4E-BP1 (no. 9452) were purchased from Cell Signaling
Technology (Danvers, MA, USA). For phosphor immunoblotting
of the phosphorylated T-loop of S6K, we employed the pan-PDK1-
site antibody from Cell Signaling Technology no. 9379) as
previously described (Collins et al, 2005). The GSK3a/b antibody
(44-610) was purchased from Biosource (Camarillo, CA, USA).
The secondary antibodies coupled to horseradish peroxidase
used for immunoblotting were obtained from Thermo Scientific
(Rockford, IL, USA).
IHC staining
Primary antibodies were used to detect B220/CD45R (RA3-6B2,
BD Pharmingen, Oxford Science Park, Oxford, UK), CD79acy
(HM57, Dako, Ely, Cambridgeshire, UK), CD3 (F7.2.38, Dako) and
Ki67 (VP-K452, Vector Laboratories, Peterborough, UK). Anti-
bodies against Akt p-473 (no. 9277), caspase-3 (no. 9662) and S6
p-S235/S236 (no. 4857) were purchased from Cell Signaling
Technology. Antibody binding was visualised using Vectastain
reagents (Vector Laboratories) and protocols performed on a Dako
immunostainer. Sections were viewed on a Nikon Eclipse E600
microscope, and digital images captured on a Nikon DXM 1200
digital camera (Nikon UK, Kingston Upon Thames, Surrey, UK).
Flow cytometric analysis
Cells were extracted from tumour and control lymph node samples
by mashing through 70mM filters into media (RPMI 1640
supplemented with 10% fetal calf serum, 100IUml
 1 penicillin,
100mgml
 1 streptomycin and 50mM b-mercaptoethanol). Cells were
then counted and 5 10
5 cells were taken per point for staining. The
following antibodies were used for staining the samples: TCRb-APC,
B220-PE, CD4-FITC, k-light-chain-PE, l-light-chain-FITC, B220-APC
(BD Pharmingen) and CD8-PECy5.5 (Invitrogen, Camarillo, CA,
USA). Live cells were identified by forward–side scatter profile. B
cells were identified by B220 expression and T cells by TCRb
expression. The k-a n dl-ratios were calculated on B220-positive cells.
RESULTS
The AZD8055 and GDC-0941 oral administrations inhibit
S6K, AKT and SGK activity within the tumours
We employed previously described PTEN
þ/ LKB1
þ/hypo mice
that are heterozygous for the expression of PTEN and express 60%
of the normal levels of LKB1 in all tissues studied (Huang et al,
2008). Approximately 90% of these mice develop spontaneously
large B-cell follicular lymphomas within cervical lymph nodes
between 6 and 8 months of age (Huang et al, 2008). To investigate
whether it was feasible to effectively inhibit the PI3K–mTOR
pathway within tumours, we treated PTEN
þ/ LKB1
þ/hypo mice
bearing visible tumours with either vehicle alone, AZD8055
(20mgkg
 1) or GDC-0941 (75mgkg
 1) once daily for 5 days.
The kinase inhibitors were well tolerated, and no changes on
overall mouse weight or health were detected during the treatment.
As previously described (Chresta et al, 2010), we observed that
GDC-0941 or AZD8055 administration induced a transient
increase in blood glucose levels (Supplementary Figure 1). This
is consistent with these compounds suppressing the PI3K–mTOR
pathway and thereby inhibiting insulin signalling and leading to
transient insulin resistance. After 5 days of treatment, tumours
were dissected and protein extracts generated. In tumour extracts
derived from PTEN
þ/ LKB1
þ/hypo mice not administered with
kinase inhibitors, a high level of Akt kinase activity and
phosphorylation of Thr308 (PDK1 site) and Ser473 (mTORC2
site) were observed (Figure 1A, chart and upper panel). As
expected, treatment with either AZD8055 or GDC-0941 led to a
marked inhibition of Akt activity as well as phosphorylation of
Thr308 and Ser473 (Figure 1A, chart and upper panel). Phospho-
rylation of the Akt substrates PRAS40 and Foxo-1/3a were also
inhibited by AZD8055 or GDC-941, but phosphorylation of GSK3a/
GSK3b, which can be regulated by multiple kinases (RSK, PKC and
PKA), was hardly affected (Figure 1A, lower panel). Inhibition of
Thr308 phosphorylation was slightly more pronounced after GDC-
0941 administration than observed with AZD8055, and similar
effect was observed in Foxo-1/3a phosphorylation (Figure 1A).
We also observed significant S6K1 activity and phosphorylation
at Thr229 (PDK1 site) and Thr389 (mTORC1 site) in tumour
extracts derived from non-drug-treated PTEN
þ/ LKB1
þ/hypo
animals (Figure 1B, chart and upper panel). The AZD8055 or
GDC-0941 treatment almost ablated S6K1 activity and suppressed
phosphorylation of Thr229 and Thr389 (Figure 1B, upper panel).
Both drugs also inhibited phosphorylation of the ribosomal S6
protein, an S6K substrate (Figure 1B, lower panel). We also
investigated the effects that these drugs had on 4E-BP1, a key
regulator of protein synthesis whose phosphorylation is induced
by the mTOR pathway (Wullschleger et al, 2006). We found that
AZD8055 and GDC-0941, to a lesser extent, induced a marked
increase in the electrophoretic mobility of 4E-BP1 within tumour
samples, which was accompanied by marked dephosphorylation of
Thr37/Thr46 and Ser65 (Figure 1C). AZD8055 or GDC-0941 did
not induce dephosphorylation of Thr70 on 4E-BP1, suggesting this
residue is not regulated by the PI 3-kinase or mTOR pathway,
which is consistent with previous work (Thoreen et al, 2009).
Currently, it is not possible to reliably assay the activity of
endogenous SGK isoforms because of lack of antibodies; hence, we
instead examined the phosphorylation of the SGK1 N-myc
downstream-regulated gene-1 (NDRG1) substrate, as readout for
SGK1 activity (Murray et al, 2004; Garcia-Martinez and Alessi,
2008). This revealed that AZD8055 or GDC-0941 also markedly
inhibited phosphorylation of endogenous NDRG1 at the site
phosphorylated by SGK1 in tumour extracts (Figure 1D).
The mTOR and PI3K inhibition impairs tumour growth
and development
We next attempted to establish how AZD8055 or GDC-0941
administration affected the progression of spontaneous B-cell
cervical follicular lymphomas in PTEN
þ/ LKB1
þ/hypo animals.
We used 6- to 8-month-old PTEN
þ/ LKB1
þ/hypo mice that had
developed externally visible tumours. At this stage, the volume of
tumours was measured by MRI, tumours were visible in the 2D
image and appeared darker than the neighbouring submaxillary
and sublingual salivary glands, whereas subcutaneous adipose
PI3K and mTOR inhibitors shrink follicular lymphomas
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Figure 2 Tumour regression induced by AZD8055 and GDC-0941 oral administration. (A) The 2D MRI images from 3D RARE-4 MRI data set of the
neck of heterozygous PTEN
þ/ LKB1
þ/hypo mouse before treatment; (i) sagittal image, (ii) ventral transverse image and (iii) anterior frontal image,
highlighting tumours (t) and submaxillary salivary gland(s). (B) Mean relative tumour volumes (normalised to their size at day 0) plotted against time. Dashed
line (triangles) indicates mice treated with vehicle alone (n¼5), black line (circles) indicates mice treated with AZD8055 (20mgkg
 1; n¼5) and grey line
(squares) represents GDC-0941 (75mgkg
 1; n¼4) treatment. (C) Ventral transverse views of 3D surface reconstructions of MRI from the neck region of
three heterozygous PTEN
þ/ LKB1
þ/hypo mice acquired first at day 0 (before treatment; i–vi), and again at day 42 (end of treatment; vii–xii). The skin is
shown in brown, tumours in pink and trachea in white.
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Figure 1 The AZD8055 and GDC-0941 oral administration suppresses PI3K downstream signalling within the tumours. The PTEN
þ/ LKB1
þ/hypo mice
bearing visible tumours were treated with either vehicle, AZD8055 (20mgkg
 1) or GDC-0941 (75mgkg
 1) once daily by oral gavage for 5 days. At 2h
after the final dose, mice were culled and tumour samples were generated. (A) The AKT was immunoprecipitated from tumour lysates, and catalytic activity
assessed employing the crosstide substrate. Each bar represents the mean specific activity±s.e. from three to five different samples, with each sample
assayed in duplicate. Tumour lysates were also analysed by immunoblotting with the indicated antibodies. (B)A si n( A), except that S6K was
immunoprecipitated and its catalytic activity assessed. (C) Tumour extracts were immunoblotted with the indicated phospho and total 4E-BP1 antibodies.
(D) SGK1 activity was assessed only by phosphorylation of the SGK1-substrate NDRG1. For each condition, immunoblots are shown with duplicate samples
derived from different mice.
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stissue was white. Other anatomical features, such as the trachea
and blood vessels, were visible and appeared black (Figure 2A).
Tumour volumes in the mice was reassessed by MRI after 2 further
weeks without drug treatment, where an increase in volume by
B15% was found (Figure 2B). The mice were then administered
daily doses of vehicle alone, AZD8055 (20mgkg
 1) or GDC-0941
(75mgkg
 1) for 42 days by oral gavage, and tumour volume was
monitored every 2 weeks (Figure 2B). Inhibitor treatment was well
tolerated, and there was no change on overall health status of the
animals at any time point analysed. Total volume of the tumours
for each mouse at each time point was measured and tabulated
(Supplementary Table 1), and normalised by assigning the tumour
volume as 1 at day 0 (before drug administration initiated). In
mice treated with vehicle, tumours continued to expand approxi-
mately linearly with a mean growth rate of 11.8±9.0mm
3 per week
(Figure 2B). Strikingly, in both AZD8055- and GDC-0941-treated
mice, there was a marked regression of tumours from days 0 to 14,
where they shrunk to B40% of their original size. After 2 weeks,
tumour shrinkage slowed and became more static, and by day 42,
the tumours treated with either inhibitor had shrunk to about half
their original size (Figure 2B). Representative tumour segmenta-
tions before treatment at day 0, and at the end of treatment at day
42, are illustrated in Figure 2C.
Effect of AZD8055 and GDC-0941 treatment on tumour
morphology
To evaluate the effect of the kinase inhibitors on tumour
morphology, an additional group of PTEN
þ/ LKB1
þ/hypo mice
bearing visible tumours was treated for 14 days, corresponding to
the maximal tumour regression observed by MRI. Necropsy was
performed, and the tissues were fixed in 10% formalin and
subjected to a detailed examination by histopathological and
immunocytochemical methods. As previously described for this
type of tumour in PTEN
þ/ LKB1
þ/hypo mice, the neck masses
were confirmed to be B-cell lymphomas (Bayascas et al, 2005;
Huang et al, 2008; Wullschleger et al, 2010). There was effacement
of the lymph node architecture associated with follicular
lymphoma (Figures 3A) showing immunoreactivity for B220/
CD45R and CD79a, and only a minority of cases showed Bcl-2
reactivity. T cells detected by anti CD3 were found in the
interfollicular areas (data not shown). The neoplastic follicles
contained a mixture of large centroblast cells and a majority of
small centrocytes (Figure 3B). The Ki67 reactivity was seen in
10–15% of follicular cells (Figure 3C). The centroblasts showed
strong cytoplasmic staining for phosphorylated ribosomal S6
protein (Figure 3E), and diffuse cytoplasmic staining of tumour
cells for Akt Ser473 phosphorylation was also detected (Figure 3F).
A comparison of tumours from the control group with those from
mice that had been treated for 2 weeks with either AZD8055 or
GDC-0941 highlights significant changes in morphology. The
lymph nodes from mice treated with AZD8055 or GDC-0941 were
smaller and show a replacement by lymphoma that was follicular
with a mixture of centrocytes and centroblasts (Figures 3G, H,
M and N). The Ki67 reactivity fell to below 5% of the neoplastic
follicular cell population (Figures 3I and O). Interestingly, there
was increased apoptosis, measured by morphology and immunor-
eactivity for activated caspase-3 (Figures 3J and P; data not
shown). Consistent with the effect of the inhibitors ablating S6K1
activity, staining for phosphorylated ribosomal S6 protein in
centroblasts was diminished in comparison with controls
(Figures 3K and Q). However, the diffuse cytoplasmic staining
for Akt Ser473 phosphorylation was still detected by immunohis-
tochemistry in treated lymphomas (Figures 3L and R).
In addition, tumour samples from mice in the longitudinal MRI
study that been treated for 42 days were also analysed by both
immunohistochemistry and immunoblot. Consistent with the
14 days data, histopathological examination of untreated animals
showed large lymph nodes with continued growth of the follicular
lymphoma showing Ki67 reactivity of 15–20% (Figure 4A, panels
a and b). There was a continued strong reactivity for phosphorylated
ribosomal S6 protein (Figure 4A, panel c). In contrast, the tumours
from animals treated with either AZD8055 or GDC-0941 had much
smaller lymph nodes and a low Ki67 reactivity (o5%; Figure 4A,
panels d, e, g and h). Plus, the staining for phosphorylated
ribosomal S6, was clearly reduced (Figure 4A, panels f and i). This
demonstrates that the inhibitor treatment after 42 days was still
effective in spite of the reduced regression of tumour growth. We
also detected a clear inhibition of the S6K1 activity measured as
phosphorylation of the ribosomal S6 protein in the immunoblot
analysis (Figure 4B, upper panel). Despite the diffuse cytoplasmic
staining for Akt Ser473 phosphorylation detected by immunohis-
tochemistry in treated lymphomas, more quantitative analysis by
western blot showed a clear suppression of Akt Ser473 and Thr308
phosphorylation (Figure 4B, medium panel). Phosphorylation of
the Akt substrates PRAS40 and Foxo-1/3a was also inhibited, again
with an enhanced effect on Foxo-1/3a phosphorylation in GDC-
0941-treated tumours (Figure 4B, medium panel). As previously
observed, no major effect on in GSK3a/GSK3b phosphorylation
was detected after inhibitor treatment (Figure 4B, medium panel).
Finally, phosphorylation of endogenous NDRG1 was also inhibited
by both AZD8055 and GDC-0941 treatments in tumour lysates
(Figure 4B, lower panel).
AZD8055 and GDC-0941 treatment effectively reduces
B-cell centroblast population
Flow cytometric analysis was also performed in healthy lymph
node samples as well as in tumour samples derived from mice
treated for 42 days. The aim was to ascertain whether the shrinkage
of the tumours induced by drug treatment represented a specific
effect on the malignant B cells.
As expected, lymphomas showed a marked increase in the
percentage of B cells compared with healthy lymph nodes
(Figure 5A). Drug treatment with either AZD8055 or GDC-0941
had no obvious effect on restoring the physiological B:T cell ratio
(Figure 5A). There was no difference in k- or l-immunoglobulin
light-chain expression between tumours or control lymph nodes
(Figure 5B). However, 95% of normal mature mouse B cells show
usage of k-light chains; hence, demonstration of light-chain
restriction is less valuable in murine than in human lymphomas
(Taddesse-Heath and Morse, 2000).
The majority of B cells found within the tumour remain small
(centrocytes), but there are an increased number of large cells
(centroblast) compared with control lymph nodes. A higher
number of large cells within the tumour signify a higher grade of
tumour and a more aggressive clinical course (Harris et al, 1999).
After excluding doublets, we quantified the centroblast population
of B cells within the tumours by forward/side scatter profile
(Figure 5C). Intriguingly, this population was dramatically reduced
by drug treatment with either AZD8055 or GDC-0941. In contrast,
no significant differences were detected between treated and
untreated tumour T-cell populations by forward/side scatter
profile (data not shown).
Tumour re-growth following cessation of drug treatment
To study the effect that cessation of drug administration had on
tumour growth, a new group of PTEN
þ/ LKB1
þ/hypo mice bearing
visible tumours was treated with either vehicle alone, AZD8055
(20mgkg
 1) or GDC-0941(75mgkg
 1) for 42 days. Consistent
with our previous results, after this treatment, tumours in drug-
treated animals diminished in volume by B50% (Figure 6A). At
day 42, drug administration ceased, and mice were monitored for
an additional 5 weeks during which tumour volume for each
mouse was analysed by MRI at days 63 and 77 and the total tumour
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svolume was normalised to its value at day 0 (Figure 6A). This data
revealed that following the removal of drug, the tumours start
growing markedly. In the case of AZD8055 treatment, tumours
reached their original size before drug administration within B30
days, and for GDC-0941, within B16 days after cessation of
treatment (Figure 6A). We also calculated the relative rates of
tumour re-growth following removal of drug by normalising total
tumour volume to its value at day 42 (cessation of treatment;
Figure 6B). The mean growth rates of tumours from days 42 to 77
were 11.8±9.0mm
3 per week (mice not treated with drug), 21.2±
5.6mm
3 per week (mice treated with AZD8055) and 29±6.5mm
3
per week (mice treated with GDC-0941; Supplementary Table 1),
indicating that the drug-treated tumours re-grew around twice the
rate of the untreated tumour.
Histopathological and immunocytochemical examination of
extracted tumours at day 77 showed that animals in the control
group showed progression from follicular to diffuse large B-cell
lymphoma, with a Ki67 rate of 15–20% and strong phosphorylated
ribosomal S6 protein reactivity (Figure 6C, panels a–d). Moreover,
and consistently with the tumour re-growth, following cessation
of either AZD8055 or GDC-0941 for 5 weeks, the morphology
of the tumours from these mice also showed a trend towards
progression to diffuse large B-cell lymphoma (Figure 6C, panels
g, f, k and l). Tumours in these animals also showed a markedly
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Figure 3 Tumour morphology after 14 days of drug treatment. At 2h after the final dose (day 14), mice (n¼3) were culled, and tumour samples were
processed for histopathological and immunocytochemical analysis. Representative sections of H&E staining ( 10 and  160 objective) and
immunohistochemistry of lymphomas using the indicated antibodies are shown. The lymphomas were all classified as B-cell follicular lymphoma by the
Bethesda criteria. (A–F) represent tumour sections from vehicle treated mice, (G–L) are sections from AZD8055 treated mice and (M–R) are sections
from GDC-0941 treated mice.
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sincreased Ki67 reactivity to 15–20% (Figure 6C, panels h and m), with
one extreme example of high-grade Burkitt-like morphology and a
Ki67 rate of 450% in one of the AZD8055-treated mouse (data not
shown). There was strong cytoplasmic staining for phosphorylated
ribosomal S6 protein in the now increased number of centroblasts
(Figure 6C, panels i and n), with no apparent difference between the
two treatment groups. The distribution of immunoreactivity for p473-
Akt appeared to be unaltered by treatment, although in those later
tumours of both treated and untreated groups that showed conversion
to diffuse large B-cell lymphoma, Akt Ser473 phosphorylation
reactivity was increased in tumour cells (Figure 6C, panels e, j and o).
Finally, we also analysed by western blot the PI3K and mTOR
downstream targets within the tumour at the end of the study.
Consistent with the above observations, we confirmed that the
PI3K–mTOR pathway was re-activated following drug removal,
and no differences were detected in high levels of phosphorylation
of endogenous NDRG1, S6K1, 4E-BP1, ribosomal S6 protein, Akt
or any of its substrates analysed between control or drug-treated
groups (Figure 6D).
DISCUSSION
In the present study, we have characterised the effect of oral
administration of the mTOR inhibitor, AZD8055, and the PI3K
inhibitor, GDC-0941, on B-cell follicular lymphoma that sponta-
neously develops in PTEN-deficient mice. Arguably, this model
of mouse tumour is more representative of a spontaneous tumour
in which the PI3K pathway is over-activated than xenograft
models, frequently employed to assess effects of signal transduc-
tion inhibitors. The drugs were well tolerated, and mice
administered the compounds for up to 6 weeks displayed no overt
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sphenotypes. The data demonstrate that the drugs effectively ablate
activation of PI3K–mTOR pathway, as emphasised by the
inhibition of Akt, S6K and SGK activity, and dephosphorylation
of key effectors of this pathway such as 4E-BP1 within the tumour.
Strikingly, AZD8055 or GDC-0941 treatment causes a marked
B40% shrinkage of tumour volume within 2 weeks, and a further
B10% reduction is observed after another 4 weeks of drug treatment.
In future work, it would be interesting to evaluate whether tumours
could be maintained at a reduced size for longer periods of time or
whether the tumours would become resistant to the drugs and start to
expand. It would also be interesting to establish whether more
frequent administration of AZD8055 or GDC-0941 to maintain
inhibition of the PI3K–mTOR pathways over a 24h period would
have a greater effect on reduction of tumour volume. Nevertheless,
the data is encouraging, as it would indicate these compounds would
offer benefit for the treatment of human cancers in which the PI3K
pathway was activated.
Our data also emphasise that further work is required to identify
the mechanisms by which tumours are maintained and do not
regress completely despite prolonged treatment with AZD8055 or
GDC-0941. More detailed analysis is required to establish whether
AZD8055 or GDC-0941 exerts a cytostatic effect and stops B-cell
follicular lymphoma cell proliferation rather than exerting a
predominant cytotoxic effect. Several widely used anti-cancer
drugs such as tamoxifen principally act by inhibiting proliferation
of tumour cells rather than inducing tumour cell death (Furr and
Jordan, 1984). Suppression of the PI3K and mTOR pathways also
reduces cell size (Wullschleger et al, 2006). It is therefore possible
that some of the regression in B-cell follicular lymphoma tumour
volume observed following GDC-0941 or AZD8055 treatment is
due to the effect of these drugs in diminishing cell size rather than
decreasing cell number. A more in-depth analysis of tumour cell
numbers and volume would be required to assess this. It is also
possible that the increase in tumour growth rate after treatment
results from a change to a more aggressive population of cells
within the tumour. Moreover, shrinkage of the tumour could
change tumour microenvironment favouring re-growth. It is also
possible that prolonged treatment with GDC-0941 or AZD8055
induces resistance of tumour cells to these compounds. This could
result in oligoclonal selection and could explain, in part, the more
rapid disease progression observed after cessation of GDC-0941 or
AZD8055 treatment (Figure 6B). In future work, it would be
important to evaluate whether tumour cells did develop resistance
to PI3K–mTOR pathway inhibitors and if so, work out the
mechanism by which this resistance occurs. It would also be
critical to investigate whether such resistance also occurs in cancer
patients being treated with these compounds in clinical trials.
In addition, our data suggest that there are no major differences
in the ability of GDC-0941 or AZD8055 to suppress growth or
activity of Akt, S6K or SGK within B-cell follicular lymphomas. The
only slight difference was that tumour re-growth following
AZD8055 cessation was slightly slower than following termination
of GDC-0941 administration (Figures 6A and B). PI3K pathway
activates several other pathways other than the mTOR–Akt/S6K/
SGK pathway including the RAC/Rho pathways that have been
implicated in cancer. There are also numerous other proteins that
possess PtdIns(3,4,5)P3-binding PH domains (Downes et al, 2007),
which could also be implicated in regulating cell growth and
proliferation downstream of PI3K. Inhibition of mTOR would not
be expected to suppress these other PI3K-regulated pathways.
However, the finding that PI3K and mTOR inhibitors have similar
effects provides further evidence that the mTOR–Akt/S6K/SGK
pathway is the most relevant axis of signalling downstream of PI3K
in regulating tumour development.
Finally, our findings also emphasise that inhibition of the PI3K
or mTOR pathway alone will not be sufficient to cause complete
regression of such tumours. Interestingly, different studies have
shown that treatment of follicular lymphoma cell lines with
combinations of PI3K/Akt/mTOR pathway inhibitors and the
proteosome inhibitor Bortezomib, or the anti-apoptotic Bcl-2
family members inhibitor ABT-263, synergise to inhibit cell
proliferation and promote apoptosis (Ackler et al, 2008; Bhende
et al, 2010). In future work, it would be interesting to analyse the
effects that combining these inhibitors with AZD8055 or GDC-0941
have on treatment of B-cell follicular lymphoma. It would also be
interesting to extend this analysis to other tumours in mice models
employing inhibitors of other components of the PI3K pathway,
such as Akt, PDK1, S6K1 and SGK isoforms, that are becoming
available. As there is also considerable emerging evidence that dual
inhibition of the PI3K and ERK pathways is more effective at
inhibiting tumourigenesis than inhibition of either pathway alone
(She et al, 2005; Carracedo et al, 2008; Engelman et al, 2008), it
may therefore be necessary to combine these inhibitors with an
inhibitor of the ERK pathway.
In summary, we have shown that studying the effect of new
drugs with a combination of MRI analysis and specific types of
spontaneously preformed tumours is capable of producing strong
preclinical data about the effectiveness of new drugs in specific
types of cancer. Our data suggest that AZD8055 and GDC-0941
treatment would offer benefit for the treatment of cancers in which
the PI3K pathway is inappropriately activated; however, new
combination strategies would need to be tested to induce the
complete regression of such tumours. We propose that the
spontaneous cancer model elaborated in our study could be
utilised to benchmark the relative effectiveness of PI3K/mTOR
inhibitors at suppressing tumour growth.
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